The Food and Drug Administration Friday updated its policies and procedures for review of generic drugs to allow expedited review of applications for new “sole-source” generic drug products. These are drugs for which there is only one approved generic equivalent for a brand-name drug. The House Committee on Oversight and Government Reform last month held a hearing examining the recent surge in prices for such drugs.